News
T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety ...
T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, according to ...
Innovative CAR-T cell therapy achieves remarkable results in patients with refractory CD30+ lymphoma
Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep Carreras Leukaemia Research Institute, have developed an innovative CAR-T cell ...
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that it will present new ...
Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback